NICE knocks-back Janssen's Imbruvica in mantle cell lymphoma
NICE | September 28, 2017
Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). In draft guidance NICE has declined to recommend Imbruvica’s use in England and Wales to treat mantle cell lymphoma.